The average one-year price target for Microbot Medical (NasdaqCM:MBOT) has been revised to $7.65 per share, reflecting a 12.50% increase from the previous estimate of $6.80 dated February 21, 2026. This new target represents a significant 191.98% rise from the latest closing price of $2.62 per share, with analyst projections ranging from a low of $5.05 to a high of $12.60 per share.
As of now, 79 funds or institutions report positions in Microbot Medical, marking a decrease of 2 owners (2.47%) over the last quarter. Institutional ownership increased by 21.20% in the past three months, totaling 12,883K shares. Notably, the put/call ratio stands at 0.10, indicating a bullish outlook among investors.
CIBC Private Wealth Group and CIBC Bancorp USA hold 1,480K and 1,454K shares, respectively, while Susquehanna International Group, LLP owns 1,245K shares and Geode Capital Management has increased its holdings to 762K shares. DnB Asset Management AS also grew its position to 677K shares, reflecting an increase of 64.04% in its portfolio allocation over the past quarter.
